[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumors":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,37,65,89,111,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100495583","assessment-of-functional-and-symptom-outcomes-for-survivors-of-paranasal-sinus-nasopharyngeal-and-skull-base-tumors-100495583",false,"NCT05733091","Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors","Inclusion criteria:\n\n1. Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report.\n2. Age ≥ 18 years\n3. Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy\n4. Ability to understand and willingness to sign written informed consent\n\nExclusion criteria:\n\n1. History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy.\n2. Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment.\n3. Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","OBSERVATIONAL","To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer",[23],"Tumors","RECRUITING","2026-04-16",{"date":27,"type":28},"2026-04-21","ACTUAL",{"date":30,"type":28},"2018-12-20",{"date":32,"type":19},"2029-12-31",{"name":34,"class":35},"M.D. Anderson Cancer Center","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":36},"100492842","phase-1-hp-pyruvate-mri-in-cancers-100492842","NCT05697406","HP Pyruvate MRI in Cancers","Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers","HC-MRI","Inclusion Criteria:\n\nClinical tumor diagnosis\n\nPatients with pre-existing MR imaging appointments\n\nMust be able to undergo MR\n\nExclusion Criteria:\n\nNo tumor diagnosis","88 Years",{"count":47,"type":19},25,"INTERVENTIONAL",[50,51],"PHASE1","PHASE2","Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.",[54,55,23],"Image","Warburg Effect","2025-09-16",{"date":58,"type":28},"2025-09-22",{"date":60,"type":28},"2024-06-24",{"date":62,"type":19},"2028-12-01",{"name":64,"class":35},"University of Maryland, Baltimore",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":48,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100388694","phase-2-protarget---a-danish-nationwide-clinical-trial-on-targeted-cancer-treatment-based-on-genomic-profiling-100388694","NCT04341181","ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","ProTarget","Inclusion Criteria:\n\n1. Patient (age≥ 18 years) with a histologically-proven locally advanced or metastatic malignant disease who is no longer benefitting from standard anti-cancer treatment or for whom, in the opinion of the investigator, no such treatment is available or indicated.\n2. ECOG performance status 0-2\n3. Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion\u002Fexclusion criteria specified in the appendix for each agent will take precedence for this and all inclusion criteria:\n\n   1. Absolute neutrophil count ≥ 1500 µl\n   2. Hemoglobin \\> 5.6 mmol\u002Fl\n   3. Platelets \\> 75,000\u002Fµl\n   4. Total bilirubin \\\u003C 1.5 x institutional upper limit of normal (ULN)\n   5. AST (SGOT) and ALT(SGPT) \\\u003C 2.5 x institutional upper limit of normal (ULN) (or \\\u003C 5 x ULN in patients with known hepatic metastases)\n   6. Calculated or measured creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2.\n4. Patients must have measurable or evaluable disease (per RECIST v1.1 for solid tumor), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable disease by physical or radiographic examination but do not meet these definitions of measurable disease are eligible and will be considered to have evaluable disease. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only) are NOT eligible, with the exception of CA-125 for ovarian cancer and PSA for prostate cancer.\n5. Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a laboratory accredited by the competent local regulatory authority. The genomic or IHC test used to qualify a patient for participation in ProTarget may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma (\"liquid biopsies\") will also be acceptable if the genomic analysis is performed in a laboratory accredited by the competent local regulatory authority.\n\n   A new biopsy must be performed if possible, for central confirmation by WGS (the result may be awaited and is not required before first dosing).\n\n   Note: Eligible genomic tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS), whole exome sequencing (WES). The test may have been performed on a fresh (frozen or in RNA-later) or paraffin-embedded specimen of the primary tumor or a metastatic deposit or on cell free DNA derived from plasma, as determined by the treating physician, and must reveal a potentially actionable genomic variant as defined in Section 5.0, or protein overexpression by IHC.\n6. Ability to understand and the willingness to sign a written informed consent\u002Fassent document\n7. Have a tumor genomic profile for which treatment with one of the approved targeted anti-cancer therapies included in this study has potential clinical benefit based on the criteria described in Section 7.0.\n8. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.\n9. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) in combination with inhibition of ovulation (intrauterine device (IUD), intrauterine hormone-releasing system ( IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence) for the duration of study participation, and for four to 24 months following completion of study therapy (depending on SPC from individual drugs). Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.\n\nExclusion Criteria:\n\n1. Ongoing toxicity \\> CTCAE grade 2, other than peripheral neuropathy, related to anti-tumor treatment that was completed within 4 weeks prior to registration. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.\n2. Previous treatment with the selected study drug for the same malignancy.\n3. If the patient's tumor has a genomic variant known to confer resistance to an anti-cancer agent available in this study, the patient will not be eligible to receive that agent but will be eligible to receive other drugs available in this study if all inclusion and exclusion criteria are met for that drug.\n4. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate cancer. These medications must have been started ≥ 1 month prior to enrollment on this study. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific exclusion criteria.\n5. Female patients who are pregnant or nursing. Male and female patients who refuse to practice highly effective contraception methods.\n6. Patients with known progressive brain metastases determined by serial imaging or declining neurologic function in the opinion of the treating physician are not eligible. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.\n\n   Additional exclusion criteria specific for GBM patients:\n   1. Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs (non-EIAED). EIAED are prohibited. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to randomization.\n   2. No radiotherapy within the three months prior to the diagnosis of progression.\n   3. No radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy unless the recurrence is histologically proven.\n7. Patients with preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.\n8. Patients with left ventricular ejection fraction (LVEF) known to be \\\u003C 40% are not eligible.\n9. Patients with stroke (including TIA) or acute myocardial infarction within 4 months before the first dose of study treatment are not eligible\n10. Patients with acute gastrointestinal bleeding within 1 month of start of treatment are not eligible.\n11. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, severe psychiatric illness situations, or anticipated or planned anti-cancer treatment or surgery.\n12. Patients who do not meet drug-specific eligibility requirements for the drug selected by the investigator, are not eligible to receive that drug.\n13. Patients whose disease is not measurable or assessable by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible.\n14. Patients with known allergy\u002Fhypersensitivity to the study drug (active substance or to any of the excipients).",{"count":18,"type":19},[51],"The ProTarget study is a phase II, prospective, non-randomized clinical trial with the primary purpose of investigating the safety and efficacy of commercially available cancer drugs that target specific changes in cancer cell DNA to treat patients with advanced cancer. The primary endpoint is anti-tumor activity or stable disease documented after 16 weeks of experimental drug treatment. The drugs used in the trial have been approved by EMA\u002FFDA for the treatment of certain cancers. Choice of drug is based on whether the patient's cancer cells contain precisely the DNA change (i) targeted by the EMA\u002FFDA-approved drug or (ii) related to sensitivity to the EMA\u002FFDA-approved drug. The trial drug is thus not approved by the EMA\u002FFDA or in Denmark for the treatment of the patient's cancer - it is so-called \"off-label use\". The secondary purposes are:\n\n* To detect side effects in patients treated with commercially available targeted cancer drugs.\n* Performing biomarker analyzes, including (but not limited to) whole-genome analysis (WGS) on a fresh tumor tissue sample (biopsy) at baseline and progression.\n* To investigate mechanisms of resistance using recurrent \u002F serial fresh tumor biopsies for WGS and so-called liquid biopsies, which are blood samples in which the cancer cell DNA is analyzed.\n\nThe secondary endpoints include response duration, progression-free survival, and overall survival.",[76,23,77,78],"Cancer","Neoplasms","Neoplasia","2025-07-22",{"date":81,"type":28},"2025-07-25",{"date":83,"type":28},"2020-08-24",{"date":85,"type":19},"2030-04-30",{"name":87,"class":35},"Ulrik Lassen",7,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":36},"100447248","cohort-of-tumors-with-poled1-mutation-100447248","NCT05103969","Cohort of Tumors With POLE\u002FD1 Mutation","Multicenter Prospective Cohort of Tumors With Pole\u002FD1 Mutation","Inclusion Criteria:\n\n* Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14) classified as pathogenic by the project working group, including: the 4 hotspots of mutations described (codons 286 (P286R\u002FH\u002FL), 411 (V411L), 459 (S459F), 424 (L424\u002FV\u002FI), (2).\n* Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12), classified as pathogenic by the project working group, including : C319Y(10).\n\nDiagnosis made from the date of launch of the cohort and in the previous year\n\n-Age ≥ 18 years\n\nExclusion Criteria:\n\n* Tumor without POLE or POLD1 mutation\n* Tumor with POLE mutation identified in research studies retrospective research\n* Opposition of the patient to the registration of his data in the cohort",{"count":97,"type":19},100,"Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)\u002FPOLD1 mutation identified by molecular biology platforms for all stages and primary sites combined",[23,100,101],"POLE Exonuclease Domain Mutation","POLD1 Gene Mutation","2024-07-05",{"date":104,"type":28},"2024-07-08",{"date":106,"type":28},"2021-10-05",{"date":108,"type":19},"2025-10-06",{"name":110,"class":35},"Federation Francophone de Cancerologie Digestive",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":48,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100280040","phase-2-the-drug-rediscovery-protocol-drup-trial-100280040","NCT02925234","The Drug Rediscovery Protocol (DRUP Trial)","A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile","DRUP","Inclusion Criteria:\n\n1. Adult (age \\>18 years) patient with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphomawith symptomatic disease progression or progression according to RECIST-criteria after standard anti-cancer treatment or for whom no such treatment is available or indicated.\n\n   \\* For patients with a primary brain tumor: Histologically confirmed recurrent or de novo primary brain tumor, with unequivocal progression after prior therapy, at least 3 months after radiotherapy (either first line chemo-radiotherapy or re-irradiation), and with stable or decreasing dosage of steroids for at least 7 days prior to the baseline MRI scan.\n2. ECOG performance status 0-2\n3. Patients must have acceptable organ function as defined below. However, specific inclusion\u002Fexclusion criteria specified in the drug-specific study manual will take precedence:\n\n   1. Absolute neutrophil count ≥ 1.5 x 109\u002Fl\n   2. Hemoglobin \\> 5.6 mmol\u002Fl\n   3. Platelets \\> 75 x 109\u002Fl\n   4. Total bilirubin \\\u003C 2 x ULN\n   5. AST (SGOT) and ALT (SGPT) \\\u003C 2.5 x institutional ULN (or \\\u003C 5 x ULN in patients with known hepatic metastases)\n   6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2\n4. Patients must have objectively measurable disease (by physical or radiographic examination, according to RECIST v1.1 for patients with solid tumors, or according to IMWG, Lugano, RANO or GCIG criteria, resp., for patients with multiple myeloma, non-Hodgkin lymphoma, glioblastoma or ovarian cancer in case of CA125-based evaluation (please refer to appendices for further details).\n5. Results must be available from a tumor genomic or protein expression test. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic deposit, in a diagnostic laboratory or within the context of another CPCT study, and must reveal a potentially actionable variant as defined in Section 5. The test results (full pathology or molecular diagnostics report) must be uploaded in the eCRF.\n6. Patients must have a tumor profile for which treatment with one of the FDA and \u002F or EMA approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information (see section 5).\n7. new (obtained ≤2 months before inclusion, and without any type of anti-cancer therapy within those ≤2 months) fresh frozen tumor biopsy specimen for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol. Alternatively, fresh frozen tumor tissue acquired in the context of a standard care procedure may be used, provided that no systemic anti-cancer treatment was given between the procedure and start of study treatment within DRUP.\n\n   The following exceptions are made:\n\n   a. An exception is made for patients with a primary brain tumor, only if the mandatory DRUP pre-treatment biopsy for biomarker analysis cannot safely be obtained:\n   1. The fresh frozen tumor biopsy sample may be replaced by fresh frozen tumor tissue, obtained earlier from recurrent disease, as part of standard of care surgical procedure (i.e., performed at progression)\n   2. If no fresh frozen tumor tissue is available for NGS, and the risk of obtaining a new tumor biopsy is considered too high, no biopsy will be required. In this case, the study coordinators must be informed in advance, and there will be no reimbursement for the biopsy procedure.\n\n   b. In case WGS is performed on tumor tissue outside the context of a clinical trial before inclusion, and without any type of anti-cancer therapy between the collection of tissue and inclusion in DRUP, this can replace the DRUP pre-treatment biopsy, provided that the patient gives consent to use his\u002Fher WGS data for biomarker analysis in DRUP.\n\n   c. An exception is made for patients that underwent an allogeneic hematopoietic stem cell transplantation prior to study enrollment, since this will prevent a correct WGS analysis due to a mismatch between the biopsy specimen and the required blood sample.\n8. Ability to understand and the willingness to sign a written informed consent document.\n9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.\n10. Because of the risks of drug treatment to the developing foetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.\n\nExclusion Criteria:\n\n1. Ongoing toxicity \\> grade 2, other than alopecia.\n2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:\n\n   * Patients suffering from CRPC are allowed to continue androgen deprivation therapy.\n   * Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.\n3. Patient is pregnant or nursing.\n4. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be stable for at least 1 month after completion of treatment and off steroid treatment prior to study enrollment.\n\n   \\* Additional exclusion criteria specific for glioblastoma patients:\n   1. Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs (non-EIAED). EIAED are prohibited. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to randomization.\n   2. No radiotherapy within the three months prior to the diagnosis of progression.\n   3. No radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy unless the recurrence is histologically proven.\n5. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.\n6. Patients with known left ventricular ejection fraction (LVEF) \\\u003C 40% are not eligible\n7. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible\n8. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness\u002Fsocial situations.\n\nFor each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. These can be found in the supplemental information about each agent included in the drug-specific study manuals. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion\u002Fexclusion criteria listed above.",{"count":120,"type":19},1550,[51],"This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must have been performed on the tumor and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Results from the molecular profiling test will be used to determine an appropriate drug(s) from among those available in the protocol. The choice of drug will be supported by a list of potential profiles, a molecular tumor board, a knowledge library and by study coordinators for review and approval of the match. The protocol-specified treatment will be administered to the patient once any drug-specific eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future genetic studies. All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment. In addition, treatment related toxicity will be evaluated.",[76,23,124,78],"Neoplasm",[126,127,128,129,130,131,132],"Molecular tumor profile","Multidisciplinary tumor board","Antitumor drugs","Molecular Targeted Therapy","Drug Repositioning","Off-Label Use","Sequence Analysis, DNA","2024-01-22",{"date":135,"type":28},"2024-01-24",{"date":137,"type":28},"2016-08",{"date":139,"type":19},"2027-12",{"name":141,"class":35},"The Netherlands Cancer Institute",36,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":150,"targetDuration":152,"studyType":20,"phases":4,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":36},"100435496","xact-ace-observational-registry-100435496","NCT04950959","XACT ACE Observational Registry","Observational Post-Market Study of the XACT ACE Robotic System","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Subjects undergoing CT-guided, minimally invasive percutaneous procedures in the interventional radiology suite\n3. Subject is willing to sign informed consent for the purposes of data collection\n\nExclusion Criteria:\n\n1\\. No exclusion criteria other than listed in the product Instructions for Use (IFU)",{"count":151,"type":19},500,"1 Day","Compile real world data on the use of the XACT ACE Robotic System",[23],[156,157,158],"CT-guided percutaneous procedure","Percutaneous biopsy","XACT ACE Robotic System","2022-10-19",{"date":161,"type":28},"2022-10-21",{"date":163,"type":28},"2021-10-01",{"date":165,"type":19},"2026-08-01",{"name":167,"class":168},"Xact Robotics Ltd.","INDUSTRY"]